Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mount Sinai researchers discover new target for vaccine development in abundant immune cells

25.07.2012
Certain white blood cells may be useful in vaccinating against blood-borne infections and HIV

White blood cells called neutrophils, which are the first line of defense against infection, play an unexpected role by boosting antibody production, according to research led by Mount Sinai School of Medicine.

The findings suggest neutrophils have multiple roles within the immune system and function at levels previously unknown to the scientific community. The research, published in Nature Immunology, provides groundbreaking insight into possible new approaches in vaccine development for blood-borne infections and HIV.

Neutrophils are part of the so-called innate immune system—the immune system encoded at birth that remains unchanged—and are at the front lines defending against infection and inflammation. The research was led by Andrea Cerutti, MD, Professor of Medicine at Mount Sinai School of Medicine, and included an international team of investigators that also involved Irene Puga, PhD, of IMIM-Hospital del Mar in Barcelona, Spain, and Montserrat Cols, PhD, of Mount Sinai.

Researchers evaluated healthy human tissues key to the immune system to assess the abundance of neutrophils in the lymph nodes, tonsils, lymphoid tissue in the intestine, and the spleen. They found very few neutrophils in all areas but one—the region of the spleen called the marginal zone. The spleen is an organ whose primary role is as a filtration system for agents that cause infection and inflammation in the body. Looking more closely at these cells, they found that their role spanned beyond the innate immune system.

According to the study, neutrophils in the marginal zone express two molecules called BAFF and APRIL, which then activate immune cells called B-cells in the adaptive immune system, which is more sophisticated and dynamic than the innate immune system. Neutrophils signal BAFF and APRIL to reprogram B-cells to create different classes of antibodies, allowing the immune system to mount a more potent antibody response.

"Our study is important because we discovered a completely new function in an immune cell that has been studied since immunology research began," said Dr. Cerutti. "The interactivity of the neutrophils in the innate immune system with the B-cells of the more sophisticated adaptive immune system shows that neutrophils operate at a much higher level than previously thought and play a very critical role in mounting a robust response to infection."

Dr. Cerutti's team also evaluated the spleens of people with a condition called neutropenia, which is characterized by a shortage in neutrophils and a compromised immune system, and found that the marginal zones in the spleens of these patients had fewer B-cells and antibodies. This demonstrates the necessity of having neutrophils interact with marginal zone B-cells to generate an innate layer of antibody defense. The fact that the research team found an abundance of neutrophils and marginal zone B-cells in the spleens from healthy individuals, but not neutropenic patients, indicates that these cells are primed and prepared to launch multi-level antibody production in healthy humans, even in the absence of a pathogen.

"Since neutrophils boost and reprogram B-cells to strengthen the immune system regardless of whether there is an infection, we may be able to harness them in vaccine development to enhance immune protection," said Dr. Cerutti. "This has significant promise in vaccinating against blood-borne infections, as B-cells are the first line of defense to antigens in the circulatory system. If we can improve vaccines with neutrophil-activating agents, we may have a chance to boost B-cell antibody production, and improve immune protection."

With this new knowledge, Dr. Cerutti and his collaborator Meimei Shan, PhD, from Mount Sinai, are evaluating neutrophil activation and B-cell antibody production in rhesus monkeys vaccinated against Simian Immunodeficiency Virus (SIV), or HIV as it occurs in monkeys, using a vaccine that includes a chemical that activates neutrophils.

"Now that we know that neutrophils are important in the release of powerful antibody-inducing molecules, such as BAFF and APRIL, neutrophils become a potential target for protective vaccines against HIV and other infectious agents," said Dr. Cerutti. "The initial results of this SIV study are encouraging and demonstrate the enormous untapped potential of neutrophils in vaccine development."

Ongoing experiments are testing the generation of antibodies to SIV and the activation of neutrophils and B-cells in the blood, spleen, and intestinal and urogenital tracts, which are major sites of SIV/HIV entry. These measurements are conducted in animals vaccinated in the presence or absence of an agent that stimulates neutrophils. Ultimately, the ability of this vaccine to generate protection against SIV will be tested after challenging the vaccinated animals with a live virus.

This study was funded by the National Institutes of Health in Bethesda, Md.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/.
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy

Mount Sinai Press Office | EurekAlert!
Further information:
http://www.mssm.edu
http://www.mountsinai.org/

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>